Safety and effectiveness of etanercept for treatment of juvenile idiopathic arthritis: Results from a postmarketing surveillance.

about

Safety and effectiveness of etanercept for treatment of juvenile idiopathic arthritis: Results from a postmarketing surveillance.

Item

http://www.wikidata.org/entity/Q38817268

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Safety and effectiveness of et ...... a postmarketing surveillance.

@en

type

Item

label

Safety and effectiveness of et ...... a postmarketing surveillance.

@en

prefLabel

Safety and effectiveness of et ...... a postmarketing surveillance.

@en

P1476

Safety and effectiveness of et ...... a postmarketing surveillance.

@en

P2093

Masaaki Mori

http://www.w3.org/2001/XMLSchema#string

Naonobu Sugiyama

http://www.w3.org/2001/XMLSchema#string

Noriko Sugiyama

http://www.w3.org/2001/XMLSchema#string

Shumpei Yokota

http://www.w3.org/2001/XMLSchema#string

Syuji Takei

http://www.w3.org/2001/XMLSchema#string

Takeshi Kokubo

http://www.w3.org/2001/XMLSchema#string

Yosuke Morishima

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.

Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis.

Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis.

Judicious use of biologicals in juvenile idiopathic arthritis.

Management of juvenile idiopathic arthritis: hitting the target.

Juvenile idiopathic arthritis and physical activity: possible inflammatory and immune modulation and tracks for interventions in young populations.

Treatment in juvenile rheumatoid arthritis and new treatment options.

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14397595.2017.1310704

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28448193

http://www.w3.org/2001/XMLSchema#string

P921

juvenile rheumatoid arthritis